Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2018 December;66(6) > Minerva Cardioangiologica 2018 December;66(6):735-43

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  TRICUSPID VALVE INTERVENTIONS 

Minerva Cardioangiologica 2018 December;66(6):735-43

DOI: 10.23736/S0026-4725.18.04757-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

The future of percutaneous tricuspid valve interventions

Damiano REGAZZOLI 1 , Antonio MANGIERI 2, Ozan DEMIR 2, Marco B. ANCONA 2, Giuseppe LANZILLO 2, Francesco GIANNINI 2, Pier P. LEONE 2, Antonio COLOMBO 2, Azeem LATIB 2, 3

1 Unit of Cardiovascular Interventions, Humanitas Research Hospital, Rozzano, Milan, Italy; 2 Unit of Cardiovascular Interventions, San Raffaele University Hospital, Milan, Italy; 3 Division of Cardiology, Department of Medicine, University of Cape Town, Cape Town, South Africa



Tricuspid valve regurgitation has a high prevalence and, when severe, is associated with poor outcomes. Nevertheless, surgical repair or replacement (isolated or as a part of a combined procedure) is rarely performed due to high surgical risk. Therefore, there is a significant unmet clinical need for percutaneous transcatheter-based treatments. Significant development in percutaneous therapies for both aortic and mitral valve disease has been accomplished over the last two decades, while transcatheter therapies for the tricuspid valve are still at an early stage. We are today at a cross-road of new transcatheter devices that are becoming available for the treatment of tricuspid regurgitation; the current review evaluates the challenges that current and future technologies have to face in order to become a safer, less invasive and equally effective alternative to surgery.


KEY WORDS: Tricuspid valve - Surgical procedures, operative - Review

inizio pagina